In contrast, there have been no preclinical and clinical data linking PPARα agonist to this type or cancer [78], neither there have been clinical data linking rosiglitazone to this type of cancer, although in a recent study rosiglitazone enhanced bladder tumors in rats pretreated with a bladder carcinogen [79]. Here, PPARA is linked to cancer.